These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23302000)

  • 1. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease.
    Rismo R; Olsen T; Cui G; Paulssen EJ; Christiansen I; Johnsen K; Florholmen J; Goll R
    Scand J Gastroenterol; 2013 Mar; 48(3):311-9. PubMed ID: 23302000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease.
    Rismo R; Olsen T; Ciu G; Paulssen EJ; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 Oct; 47(10):1200-10. PubMed ID: 22861799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease.
    Song L; Hanlon DW; Chang L; Provuncher GK; Kan CW; Campbell TG; Fournier DR; Ferrell EP; Rivnak AJ; Pink BA; Minnehan KA; Patel PP; Wilson DH; Till MA; Faubion WA; Duffy DC
    J Immunol Methods; 2011 Sep; 372(1-2):177-86. PubMed ID: 21821036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
    Stallmach A; Giese T; Schmidt C; Ludwig B; Mueller-Molaian I; Meuer SC
    Int J Colorectal Dis; 2004 Jul; 19(4):308-15. PubMed ID: 14605835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.
    Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
    Aliment Pharmacol Ther; 2004 Mar; 19(6):671-8. PubMed ID: 15023169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
    Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
    Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.
    Amiot A; Setakhr V; Seksik P; Allez M; Treton X; De Vos M; Laharie D; Colombel JF; Abitbol V; Reimund JM; Moreau J; Veyrac M; Flourié B; Cosnes J; Lemann M; Bouhnik Y
    Am J Gastroenterol; 2014 Sep; 109(9):1443-9. PubMed ID: 25091063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.
    Olsen T; Cui G; Goll R; Husebekk A; Florholmen J
    Scand J Gastroenterol; 2009; 44(6):727-35. PubMed ID: 19294580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of soluble cytokine receptors in Crohn's disease.
    Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
    Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
    Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
    Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.